Oric Pharmaceuticals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Oric Pharmaceuticals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($129.47M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($127.85M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($100.70M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($89.12M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($78.72M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($73.70M) | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | ($26.88M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | ($21.36M) | Mar 23, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($143.00M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($142.90M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($110.78M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($91.77M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($78.87M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($74.19M) | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | ($28.57M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | ($22.37M) | Mar 23, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($110.97M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($112.66M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($85.69M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($75.14M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($59.54M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($45.27M) | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | ($23.53M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | ($20.68M) | Mar 23, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $712.0K | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $1.19M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $849.0K | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.08M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $939.0K | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $667.0K | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | $768.0K | Mar 21, 2022 |
| FY2020 | Dec 31, 2018 | $525.0K | Mar 23, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $408.89M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $274.14M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $252.01M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $247.18M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $298.64M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $299.00M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $94.09M | Mar 23, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.53M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $31.02M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $27.92M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $24.83M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $25.67M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $9.22M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | $6.12M | Mar 23, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $384.36M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $243.12M | Feb 23, 2026 |
| FY2025 | Dec 31, 2023 | $224.09M | Feb 23, 2026 |
| FY2024 | Dec 31, 2022 | $222.35M | Feb 18, 2025 |
| FY2023 | Dec 31, 2021 | $272.98M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $289.78M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($90.08M) | Mar 21, 2022 |
| FY2021 | Dec 31, 2018 | ($64.43M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2017 | ($43.61M) | Mar 23, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($692.24M) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | ($562.77M) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | ($434.93M) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | ($334.23M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($245.11M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($166.39M) | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | ($92.69M) | Mar 23, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.67M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | $59.41M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | $23.38M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | $66.84M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $226.01M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $78.45M | Mar 21, 2022 |
| FY2021 | Dec 31, 2019 | $89.16M | Mar 21, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $10.50M | Mar 21, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 16, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 98.53M | Feb 23, 2026 |
| FY2025 | Dec 31, 2024 | 71.02M | Feb 23, 2026 |
| FY2024 | Dec 31, 2023 | 54.87M | Feb 18, 2025 |
| FY2023 | Dec 31, 2022 | 45.09M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 39.43M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | 36.67M | Mar 21, 2022 |
| FY2020 | Dec 31, 2019 | 1.98M | Mar 23, 2021 |